# Covid-19 Vaccine Response in Immunocompromised Haematology Patients

> **NCT04805216** · — · COMPLETED · sponsor: **University Hospitals of North Midlands NHS Trust** · enrollment: 75 (actual)

## Conditions studied

- Covid19
- Haematological Disorders
- Immune Suppression

## Interventions

- **PROCEDURE:** Blood test

## Key facts

- **NCT ID:** NCT04805216
- **Lead sponsor:** University Hospitals of North Midlands NHS Trust
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-07-31
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04805216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04805216, "Covid-19 Vaccine Response in Immunocompromised Haematology Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04805216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*